Cell-based therapy using miR-302-367 expressing cells represses glioblastoma growth

Mohamed Fareh, Fabien Almairac, Laurent Turchi, Fanny Burel-Vandenbos, Philippe Paquis, Denys Fontaine, Sandra Lacas-Gervais, Marie Pierre Junier, Hervé Chneiweiss, Thierry Virolle*

*Corresponding author for this work

Research output: Contribution to journalArticleScientificpeer-review

54 Citations (Scopus)
72 Downloads (Pure)


Glioblastomas are incurable primary brain tumors that affect patients of all ages. The aggressiveness of this cancer has been attributed in part to the persistence of treatment-resistant glioblastoma stem-like cells. We have previously discovered the tumor-suppressor properties of the microRNA cluster miR-302-367, representing a potential treatment for glioblastoma. Here, we attempted to develop a cell-based therapy by taking advantage of the capability of glioma cells to secrete exosomes that enclose small RNA molecules. We engineered primary glioma cells to stably express the miR-302-367. Remarkably, these cells altered, in a paracrine-dependent manner, the expression of stemness markers, the proliferation and the tumorigenicity of neighboring glioblastoma cells. Further characterization of the secretome derived from miR-302-367 expressing cells showed that a large amount of miR-302-367 was enclosed in exosomes, which were internalized by the neighboring glioblastoma cells. This miR-302-367 cell-To-cell transfer resulted in the inhibition of its targets such as CXCR4/SDF1, SHH, cyclin D, cyclin A and E2F1. Orthotopic xenograft of miR-302-367-expressing cells together with glioblastoma stem-like cells efficiently altered the tumor development in mice brain.

Original languageEnglish
Article numbere2713
Number of pages11
JournalCell Death and Disease
Issue number3
Publication statusPublished - 2017


Dive into the research topics of 'Cell-based therapy using miR-302-367 expressing cells represses glioblastoma growth'. Together they form a unique fingerprint.

Cite this